Investments on New Facilities, Marketing Grants, Commercial Releases, and Trial Results - Research Report on AstraZeneca, Theravance, Accuray, Volcano, and Auxilium

Editor Note: For more information about this release, please scroll to bottom.

News provided by

Nov 21, 2013, 08:00 ET

NEW YORK, November 21, 2013 /PRNewswire/ --

Today, Analysts' Corner announced new research reports highlighting AstraZeneca plc (NYSE: AZN), Theravance, Inc. (NASDAQ: THRX), Accuray, Inc. (NASDAQ: ARAY), Volcano Corporation (NASDAQ: VOLC), and Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.

AstraZeneca plc Research Report

On November 11, 2013, AstraZeneca plc (AstraZeneca) announced that it intends to invest £120 million ($190 million) in a new facility at its global manufacturing site in Macclesfield, UK to continue production of Zoladex, an injectable treatment for prostate cancer. The Company stated that this investment secures 300 existing Zoladex jobs at the site and will create over 200 temporary jobs during the construction and commissioning phase until early 2017. David Smith, Executive Vice President of Operations at AstraZeneca stated, "Zoladex is one of AstraZeneca's leading cancer drugs, supplied to patients across the globe. This new facility will support the continued production of this important medicine in the UK." According to the Company, the construction of the new facility will begin in 2013 and will be due for completion in 2016. In addition, AstraZeneca stated that the products manufactured in the new facility will begin to be supplied to markets in 2017. The Full Research Report on AstraZeneca plc - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/09cc_AZN

Theravance, Inc. Research Report

On November 18, 2013, Theravance, Inc. (Theravance), together with GSK, announced that the European Commission has granted marketing authorization for RELVAR® ELLIPTA®, now licensed across 31 European countries for asthma and COPD. Darrell Baker, Senior Vice President and Head of GSK Global Respiratory stated, "We are delighted that Relvar Ellipta is now licensed, which means that healthcare professionals across Europe will have the option to prescribe an ICS/LABA that offers 24-hour efficacy from a once-daily dose, delivered in our new Ellipta inhaler." Rick E Winningham, CEO of Theravance, added, "We are delighted that another significant regulatory body has granted marketing authorisation for Relvar Ellipta for the treatment of asthma and COPD and look forward to seeing the benefits of this effective once-daily treatment option in these patient populations." The Full Research Report on Theravance, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/fa70_THRX

Accuray, Inc. Research Report

On November 18, 2013, Accuray, Inc. (Accuray) announced that its management will present at the Piper Jaffray 25^th Annual Healthcare Conference in New York on December 4, 2013 at 1:00 p.m. EST / 10:00 a.m. PST. The Company added that a live webcast of the presentation will be available online via the Investor Relations page of the Company website. Accuray further stated that a webcast replay of the presentation can be accessed approximately one hour after the live presentation concludes and will be available for about 30 days following the event. The Full Research Report on Accuray, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/36bf_ARAY

Volcano Corporation Research Report

On November 13, 2013, Volcano Corporation (Volcano) announced the commercial release and initial implantations of its Crux® Vena Cava Filter (VCF) in patients at risk for recurrent pulmonary embolism (PE). The Company stated that it is the only filter with a double helical design that self-centers to help prevent filter tilt and offers the Bi-Trieval™ option of retrieval via either the jugular or femoral vein. Thomas Fogarty, M.D., Founder of Crux Biomedical (which developed the Crux VCF and was acquired by Volcano in 2012) stated, "The Crux VCF represents the first major design innovation for IVC filters in decades. Its unique self-centering design addresses the risks of migration and tilt, provides filtration across the entire lumen of the vessel, and provides for the Bi-Trieval™ option of either femoral or jugular retrieval." Neil Hattangadi, M.D., Vice President and General Manager of Volcano's Peripheral Vascular Business Unit added, "This milestone represents one of many recent developments at Volcano that demonstrates the company's commitment to expanding our peripheral product offering and building on our heritage in diagnostics to deliver new therapeutic solutions for the patients and physicians we serve." The Full Research Report on Volcano Corporation - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/14bf_VOLC

Auxilium Pharmaceuticals, Inc. Research Report

On November 18, 2013, Auxilium Pharmaceuticals, Inc. (Auxilium) announced the results of the MULTICORD study, an open-label, Phase 3b study of the treatment of multiple joints injected concurrently. According to the Company, the study revealed that two concurrent injections of XIAFLEX® in patients with multiple Dupuytren's contractures resulted in an improvement in joint contracture and range of motion, compared to those seen in previous studies when XIAFLEX was administered as single injections, 30 days apart. Auxilium stated that the results of the trial and the earlier MULTICORD studies support Auxilium's planned supplemental Biologics License Application (sBLA) submission to the U.S. Food and Drug Administration (FDA) in Q1 2014, in order to expand the labeling for the concurrent treatment of multiple palpable cords. The Full Research Report on Auxilium Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/86a4_AUXL

----

EDITOR NOTES:

This is not company news. We are an independent source and our views do not reflect the companies mentioned.
Information in this release is fact checked and produced on a best efforts basis and reviewed by Namrata Maheshwari, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at [email protected].
For any urgent concerns or inquiries, please contact us at [email protected].
Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to [email protected] for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Namrata Maheshwari, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

AnalystsCorner.com

SOURCE Analysts' Corner